MLYS
Mineralys Therapeutics, Inc.
Key Financials
Operating Income
$-170604000
↑ 11.3%
Net Income
$-154651000
↑ 13.0%
Total Assets
$661.8M
↑ 221.4%
EPS (Diluted)
$-2.29
↑ 37.4%
Shareholders' Equity
$646.7M
↑ 238.1%
Cash & Equivalents
$172.9M
↑ 51.6%
Operating Cash Flow
$-142416000.00
↑ 14.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 4/17/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 4 | 4/15/2026 | View on SEC |
| 144 | 4/15/2026 | View on SEC |
| 4 | 4/13/2026 | View on SEC |
| 144 | 4/13/2026 | View on SEC |
| 144 | 4/13/2026 | View on SEC |
| ARS | 4/10/2026 | View on SEC |
| 144 | 4/9/2026 | View on SEC |
| DEFA14A | 4/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MLYS |
| Company Name | Mineralys Therapeutics, Inc. |
| CIK | 1933414 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (888) 378-6240 |